Skip to main content
49°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Verastem Oncology
< Previous
1
2
3
Next >
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
December 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
December 13, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
November 13, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 08, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
November 07, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
November 06, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
October 26, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
October 14, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
September 28, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Participate in Upcoming Investor Conferences
September 05, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
August 28, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 08, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
July 11, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
July 05, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
June 16, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 15, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Reverse Stock Split
May 31, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
May 25, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
May 16, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Participate in Upcoming Investor Conferences
May 01, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
April 26, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
April 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
March 15, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
March 14, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.